60 Degrees Pharmaceuticals (SCTP) H.C. Wainwright 28th Annual Global Investment Conference summary

Financial highlights and position

• Market cap is approximately $4 million, with preferred shares convertible at company discretion.

• Commercial sales of ARAKODA are growing despite limited promotional spend.

• A $1 million funding round in July provides runway through October, coinciding with a key clinical milestone.

Strategic focus and pipeline development

• Focused on expanding ARAKODA's label from malaria prevention to babesiosis, a tick-borne disease.

• Pipeline also targets post-treatment Lyme disease and alpha-gal syndrome, both with high unmet medical need.

• Pursuing label expansions for tafenoquine in veterinary and human babesiosis indications, with phase II and pivotal trials underway.

Clinical rationale and evidence

• Tafenoquine offers weekly dosing, broad spectrum, and a strong safety profile from over 1,100 patients in clinical studies.

• Non-clinical and recent human case studies show tafenoquine, especially combined with atovaquone, is effective in treatment-refractory babesiosis.

• Addition of babesiosis indication could nearly triple the asset's value due to longer treatment duration.